TORONTO, ON and REHOVOT, ISRAEL--(Marketwired - June 16, 2016) - VAXIL BIO LTD. (TSX VENTURE: VXL), an Israeli biotech specializing in immuno-oncology, reports that it has successfully received a Notice of Allowance to Grant a Patent from the European Patent Office for Patent Application No. 07827143.4 entitled "Antigen Specific Multi Epitope Vaccines".
"This is a major patent for Vaxil and our team has been working towards this for a long time. Vaxil is very excited about having broad IP protection in the European Union, covering the VaxHit™ platform and all immunotherapy products derived from it. This of course includes Vaxil's lead, Orphan Drug Designated immunotherapy ImMucin™. Perhaps even more importantly, however, is the protection this patent affords VaxHit™ as a platform with potential to generate additional immunotherapies targeting a range of cancer antigens in the uniquely advantageous manner through which ImMucin™ has targeted MUC1," commented Vaxil Founder Dr. Lior Carmon.
Vaxil's VaxHit™ platform technology combines proprietary algorithms which enable in-silico identification of signal peptides domains and their subsequent use as immunotherapeutic products. The VaxHit™ platform is essentially a launchpad for novel and uniquely targeted immunotherapy products. In the case of MUC1, a renowned yet still unsuccessfully targeted cancer antigen, Vaxil utilized its VaxHit™ platform in order to isolate a 21-mer lead product now known as ImMucin™. A Phase-I/II clinical trial with 15 myeloma cancer patients served to validate strong immunotherapeutic potential. The trial also served to endorse VaxHit™'s potential as a platform for generating products with the ability to target renowned cancer antigens in an altogether novel and effective way.
Read more: http://www.marketwired.com/press-release/vaxil-receives-positive-response-from-european-patent-office-allowance-immunotherapy-tsx-venture-vxl-2134984.htm